Symbols / ALDX
ALDX Chart
About
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 313.45M |
| Enterprise Value | 253.69M | Income | -43.19M | Sales | — |
| Book/sh | 0.82 | Cash/sh | 1.25 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | 13.36 | PEG | — |
| P/S | — | P/B | 6.36 | P/C | — |
| EV/EBITDA | -5.65 | EV/Sales | — | Quick Ratio | 2.64 |
| Current Ratio | 2.72 | Debt/Eq | 31.56 | LT Debt/Eq | — |
| EPS (ttm) | -0.73 | EPS next Y | 0.39 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -28.94% |
| ROE | -64.31% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 60.16M |
| Shs Float | 48.61M | Short Float | 8.99% | Short Ratio | 6.22 |
| Short Interest | — | 52W High | 7.20 | 52W Low | 1.14 |
| Beta | 0.96 | Avg Volume | 1.07M | Volume | 1.04M |
| Target Price | $9.67 | Recom | None | Prev Close | $4.99 |
| Price | $5.21 | Change | 4.41% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.67
Mean price target
2. Current target
$5.21
Latest analyst target
3. DCF / Fair value
$4.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.21
Low
$7.00
High
$13.00
Mean
$9.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-10 | reit | BTIG | Buy → Buy | $9 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-04-07 | main | BTIG | Buy → Buy | $9 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-08-02 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-05-06 | reit | Oppenheimer | Outperform → Outperform | $10 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2024-04-03 | up | Oppenheimer | Perform → Outperform | $10 |
| 2023-10-17 | main | Citigroup | Buy → Buy | $8 |
| 2023-10-17 | down | Oppenheimer | Outperform → Perform | — |
| 2023-08-09 | reit | Oppenheimer | Outperform → Outperform | $14 |
| 2023-06-30 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-22 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-06-01 | main | Citigroup | Buy → Buy | $25 |
| 2023-05-05 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-03-10 | main | Citigroup | Buy → Buy | $28 |
| 2023-03-10 | reit | HC Wainwright & Co. | — → Buy | $15 |
- Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Yahoo Finance hu, 19 Feb 2026 14
- Understanding Momentum Shifts in (ALDX) - Stock Traders Daily Fri, 20 Feb 2026 06
- Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research Fri, 20 Feb 2026 01
- Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan Wed, 18 Feb 2026 12
- Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha ue, 16 Dec 2025 08
- New Analyst Forecast: $ALDX Given $9.0 Price Target | ALDX Stock News - Quiver Quantitative Mon, 10 Nov 2025 08
- Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet? - simplywall.st hu, 27 Nov 2025 08
- Why Is Aldeyra Therapeutics Stock Falling Tuesday? - Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga ue, 16 Dec 2025 08
- Jefferies raises Aldeyra Therapeutics stock price target to $7 on FDA acceptance - Investing.com Wed, 08 Oct 2025 07
- Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance Mon, 08 Dec 2025 08
- Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha ue, 30 Dec 2025 08
- Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily Mon, 09 Feb 2026 08
- Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st Sun, 06 Jul 2025 07
- Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance ue, 03 Feb 2026 08
- Mid to low cap healthcare stocks with the strongest earnings momentum (ALDX:NASDAQ) - Seeking Alpha Fri, 16 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2500 | 13250 | — | Purchase at price 5.30 per share. | ALFIERI MICHAEL L | Chief Financial Officer | — | 2025-08-13 00:00:00 | D |
| 1 | 22073 | 113713 | — | Sale at price 5.15 per share. | MACHATHA STEPHEN | Officer | — | 2025-08-11 00:00:00 | D |
| 2 | 3400000 | 4828000 | — | Sale at price 1.42 per share. | PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | — | 2025-04-03 00:00:00 | I |
| 3 | 16041 | 75975 | — | Sale at price 4.74 per share. | MACHATHA STEPHEN | Officer | — | 2024-08-12 00:00:00 | D |
| 4 | 10834 | 51313 | — | Sale at price 4.74 per share. | GREENBERG BRUCE | Chief Financial Officer | — | 2024-08-12 00:00:00 | D |
| 5 | 177993 | 833867 | — | Purchase at price 4.67 - 4.74 per share. | PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-05 00:00:00 | I |
| 6 | 504272 | 1934505 | — | Purchase at price 3.25 - 4.09 per share. | PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-03 00:00:00 | I |
| 7 | 183238 | 580760 | — | Sale at price 3.05 - 3.27 per share. | BRADY TODD C | Chief Executive Officer | — | 2024-03-12 00:00:00 | D |
| 8 | 29768 | 98605 | — | Sale at price 3.16 - 3.41 per share. | MACHATHA STEPHEN | Officer | — | 2024-03-12 00:00:00 | D |
| 9 | 13201 | 44968 | — | Sale at price 3.41 per share. | GREENBERG BRUCE | Chief Financial Officer | — | 2024-03-11 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -53.68M | -35.21M | -60.07M | -55.77M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -55.85M | -37.54M | -62.02M | -57.78M |
| ReconciledDepreciation | 249.62K | 262.78K | 258.71K | 264.18K |
| EBITDA | -53.68M | -35.21M | -60.07M | -55.77M |
| EBIT | -53.93M | -35.47M | -60.33M | -56.03M |
| NetInterestIncome | 4.27M | 5.25M | 655.35K | -1.56M |
| InterestExpense | 1.93M | 2.07M | 1.69M | 1.74M |
| InterestIncome | 6.19M | 7.32M | 2.35M | 185.36K |
| NormalizedIncome | -55.85M | -37.54M | -62.02M | -57.78M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -55.85M | -37.54M | -62.02M | -57.78M |
| TotalExpenses | 60.12M | 42.79M | 62.68M | 56.22M |
| TotalOperatingIncomeAsReported | -60.12M | -42.79M | -62.68M | -56.22M |
| DilutedAverageShares | 59.48M | 58.94M | 58.41M | 54.04M |
| BasicAverageShares | 59.48M | 58.94M | 58.41M | 54.04M |
| DilutedEPS | -0.94 | -0.64 | -1.06 | -1.07 |
| BasicEPS | -0.94 | -0.64 | -1.06 | -1.07 |
| DilutedNIAvailtoComStockholders | -55.85M | -37.54M | -62.02M | -57.78M |
| NetIncomeCommonStockholders | -55.85M | -37.54M | -62.02M | -57.78M |
| NetIncome | -55.85M | -37.54M | -62.02M | -57.78M |
| NetIncomeIncludingNoncontrollingInterests | -55.85M | -37.54M | -62.02M | -57.78M |
| NetIncomeContinuousOperations | -55.85M | -37.54M | -62.02M | -57.78M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -55.85M | -37.54M | -62.02M | -57.78M |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 4.27M | 5.25M | 655.35K | -1.56M |
| InterestExpenseNonOperating | 1.93M | 2.07M | 1.69M | 1.74M |
| InterestIncomeNonOperating | 6.19M | 7.32M | 2.35M | 185.36K |
| OperatingIncome | -60.12M | -42.79M | -62.68M | -56.22M |
| OperatingExpense | 60.12M | 42.79M | 62.68M | 56.22M |
| ResearchAndDevelopment | 48.22M | 29.46M | 47.31M | 44.94M |
| SellingGeneralAndAdministration | 11.89M | 13.34M | 15.37M | 11.28M |
| GeneralAndAdministrativeExpense | 11.89M | 13.34M | 15.37M | 11.28M |
| OtherGandA | 11.89M | 13.34M | 15.37M | 11.28M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 59.65M | 59.20M | 58.56M | 58.08M |
| ShareIssued | 59.65M | 59.20M | 58.56M | 58.08M |
| TotalDebt | 15.30M | 15.66M | 16.08M | 15.86M |
| TangibleBookValue | 71.00M | 119.80M | 151.01M | 205.74M |
| InvestedCapital | 86.04M | 134.94M | 166.84M | 221.24M |
| WorkingCapital | 85.47M | 125.55M | 165.66M | 220.98M |
| NetTangibleAssets | 71.00M | 119.80M | 151.01M | 205.74M |
| CapitalLeaseObligations | 271.63K | 510.81K | 249.26K | 354.84K |
| CommonStockEquity | 71.00M | 119.80M | 151.01M | 205.74M |
| TotalCapitalization | 86.00M | 119.80M | 165.93M | 221.24M |
| TotalEquityGrossMinorityInterest | 71.00M | 119.80M | 151.01M | 205.74M |
| StockholdersEquity | 71.00M | 119.80M | 151.01M | 205.74M |
| GainsLossesNotAffectingRetainedEarnings | 37.44K | 0.00 | -103.94K | 0.00 |
| OtherEquityAdjustments | 37.44K | -103.94K | ||
| RetainedEarnings | -450.11M | -394.26M | -356.72M | -294.69M |
| AdditionalPaidInCapital | 521.02M | 513.99M | 507.77M | 500.37M |
| CapitalStock | 59.65K | 59.20K | 58.56K | 58.08K |
| CommonStock | 59.65K | 59.20K | 58.56K | 58.08K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 33.60M | 28.53M | 30.28M | 27.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 15.00M | 6.27M | 14.92M | 15.63M |
| NonCurrentDeferredLiabilities | 0.00 | 6.00M | 0.00 | |
| NonCurrentDeferredRevenue | 0.00 | 6.00M | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 15.00M | 271.63K | 14.92M | 15.63M |
| LongTermCapitalLeaseObligation | 0.00 | 271.63K | 0.00 | 125.23K |
| LongTermDebt | 15.00M | 14.92M | 15.50M | |
| CurrentLiabilities | 18.60M | 22.26M | 15.36M | 11.77M |
| CurrentDeferredLiabilities | 6.00M | 0.00 | ||
| CurrentDeferredRevenue | 6.00M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 303.00K | 15.39M | 1.16M | 229.61K |
| CurrentCapitalLeaseObligation | 271.63K | 239.18K | 249.26K | 229.61K |
| CurrentDebt | 31.37K | 15.15M | 911.76K | |
| OtherCurrentBorrowings | 31.37K | 15.15M | 911.76K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.33M | 3.09M | 3.82M | 1.51M |
| PayablesAndAccruedExpenses | 7.97M | 3.79M | 10.38M | 10.03M |
| CurrentAccruedExpenses | 7.79M | 2.45M | 10.24M | 9.01M |
| Payables | 180.45K | 1.34M | 133.62K | 1.02M |
| AccountsPayable | 180.45K | 1.34M | 133.62K | 1.02M |
| TotalAssets | 104.61M | 148.33M | 181.29M | 233.14M |
| TotalNonCurrentAssets | 534.22K | 516.58K | 268.54K | 384.35K |
| NonCurrentDeferredAssets | 267.26K | 0.00 | ||
| NetPPE | 266.95K | 516.58K | 268.54K | 384.35K |
| GrossPPE | 266.95K | 516.58K | 268.54K | 384.35K |
| OtherProperties | 266.95K | 516.58K | 268.54K | 384.35K |
| CurrentAssets | 104.07M | 147.81M | 181.02M | 232.75M |
| OtherCurrentAssets | 301.15K | 183.15K | 442.72K | 93.46K |
| CurrentDeferredAssets | 2.21M | 4.46M | 2.61M | 2.40M |
| PrepaidAssets | 408.09K | 340.39K | 432.23K | 435.41K |
| Receivables | 0.00 | 3.24M | 28.77K | |
| OtherReceivables | 3.24M | 28.77K | ||
| CashCashEquivalentsAndShortTermInvestments | 101.15M | 142.82M | 174.30M | 229.79M |
| OtherShortTermInvestments | 46.62M | 0.00 | 29.88M | 0.00 |
| CashAndCashEquivalents | 54.53M | 142.82M | 144.42M | 229.79M |
| CashEquivalents | 30.79M | 14.31M | 9.27M | 129.43M |
| CashFinancial | 23.73M | 128.51M | 135.15M | 100.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -43.21M | -30.33M | -56.65M | -42.56M |
| RepaymentOfDebt | -292.50K | -1.04M | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 189.81M | ||
| CapitalExpenditure | -16.32K | -7.81K | ||
| InterestPaidSupplementalData | 1.75M | 1.70M | 1.34M | 1.34M |
| EndCashPosition | 54.53M | 142.82M | 144.42M | 229.79M |
| BeginningCashPosition | 142.82M | 144.42M | 229.79M | 77.86M |
| ChangesInCash | -88.30M | -1.60M | -85.37M | 151.93M |
| FinancingCashFlow | -171.42K | -1.27M | 1.22M | 194.50M |
| CashFlowFromContinuingFinancingActivities | -171.42K | -1.27M | 1.22M | 194.50M |
| NetOtherFinancingCharges | -267.26K | -532.95K | ||
| ProceedsFromStockOptionExercised | 388.34K | 305.23K | 1.22M | 4.68M |
| NetCommonStockIssuance | 0.00 | 189.81M | ||
| CommonStockIssuance | 0.00 | 189.81M | ||
| NetIssuancePaymentsOfDebt | -292.50K | -1.04M | 0.00 | |
| NetLongTermDebtIssuance | -292.50K | -1.04M | 0.00 | |
| LongTermDebtPayments | -292.50K | -1.04M | 0.00 | |
| InvestingCashFlow | -44.92M | 30.00M | -29.95M | -7.81K |
| CashFlowFromContinuingInvestingActivities | -44.92M | 30.00M | -29.95M | -7.81K |
| NetInvestmentPurchaseAndSale | -44.92M | 30.00M | -29.94M | 0.00 |
| SaleOfInvestment | 52.00M | 30.00M | 63.00M | 0.00 |
| PurchaseOfInvestment | -96.92M | 0.00 | -92.94M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -16.32K | -7.81K | |
| PurchaseOfPPE | 0.00 | -16.32K | -7.81K | |
| OperatingCashFlow | -43.21M | -30.33M | -56.64M | -42.56M |
| CashFlowFromContinuingOperatingActivities | -43.21M | -30.33M | -56.64M | -42.56M |
| ChangeInWorkingCapital | 5.91M | 861.18K | -3.44M | 7.44M |
| ChangeInOtherWorkingCapital | 6.00M | |||
| ChangeInPayablesAndAccruedExpense | 3.85M | -6.87M | 316.31K | 5.20M |
| ChangeInAccruedExpense | 5.00M | -8.08M | 1.20M | 4.56M |
| ChangeInPayable | -1.16M | 1.20M | -886.08K | 638.06K |
| ChangeInAccountPayable | -1.16M | 1.20M | -886.08K | 638.06K |
| ChangeInPrepaidAssets | 2.07M | 1.73M | -3.76M | 2.24M |
| OtherNonCashItems | 177.33K | 354.19K | 331.15K | 409.47K |
| StockBasedCompensation | 7.97M | 5.75M | 8.29M | 7.11M |
| AmortizationOfSecurities | -1.67M | -14.54K | -47.24K | 0.00 |
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 249.62K | 262.78K | 258.71K | 264.18K |
| DepreciationAndAmortization | 249.62K | 262.78K | 258.71K | 264.18K |
| NetIncomeFromContinuingOperations | -55.85M | -37.54M | -62.02M | -57.78M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALDX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|